Van Hulzen Asset Management LLC Acquires Shares of 116,555 Danaher Corporation $DHR

Van Hulzen Asset Management LLC bought a new position in shares of Danaher Corporation (NYSE:DHR – Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 116,555 shares of the conglomerate’s stock, valued at approximately $22,201,000. Danaher comprises about 1.6% of Van Hulzen Asset Management LLC’s investment portfolio, making the stock its 18th largest holding.

A number of other large investors have also made changes to their positions in DHR. BlackRock Inc. acquired a new stake in shares of Danaher in the second quarter valued at approximately $10,492,520,000. Norges Bank acquired a new position in Danaher during the fourth quarter worth $2,177,106,000. Generation Investment Management LLP acquired a new position in Danaher during the second quarter worth $1,287,949,000. Flossbach Von Storch SE purchased a new stake in Danaher in the 2nd quarter valued at $747,260,000. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Danaher in the 2nd quarter worth $712,875,000. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Get Danaher alerts:

Danaher Stock Performance

NYSE DHR opened at $215.18 on Tuesday. The stock has a fifty day simple moving average of $196.49 and a 200-day simple moving average of $192.39. The company has a current ratio of 1.65, a quick ratio of 1.25 and a debt-to-equity ratio of 0.48. The stock has a market cap of $151.27 billion, a PE ratio of 38.22, a P/E/G ratio of 2.72 and a beta of 0.78. Danaher Corporation has a twelve month low of $160.93 and a twelve month high of $242.80.

Danaher (NYSE:DHR – Get Free Report) last issued its quarterly earnings data on Monday, July 20th. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.85 by $0.09. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The firm had revenue of $6.26 billion for the quarter, compared to analyst estimates of $6.12 billion. During the same period in the previous year, the firm earned $0.77 EPS. Danaher’s revenue was up 5.5% on a year-over-year basis. Equities analysts anticipate that Danaher Corporation will post 8.53 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms have recently commented on DHR. HSBC reduced their price target on Danaher from $270.00 to $230.00 and set a “buy” rating on the stock in a report on Wednesday, June 3rd. Citigroup started coverage on shares of Danaher in a research report on Tuesday, May 26th. They set a “buy” rating and a $230.00 price objective for the company. Piper Sandler initiated coverage on shares of Danaher in a research note on Thursday, June 11th. They set a “neutral” rating and a $200.00 target price on the stock. Royal Bank Of Canada boosted their target price on shares of Danaher from $200.00 to $215.00 and gave the company an “outperform” rating in a report on Wednesday, July 22nd. Finally, DZ Bank assumed coverage on shares of Danaher in a research note on Wednesday, June 3rd. They issued a “buy” rating and a $210.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $228.91.

Check Out Our Latest Stock Analysis on DHR

About Danaher

(Free Report)

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.

Recommended Stories

• Five stocks we like better than Danaher
• Visa Just Put Hims & Hers in the Penalty Box—Here’s Why It Matters
• Treasury Yields Are Surging Again: 3 Stocks That Could Feel the Pain
• Snowflake Could Be Headed for New Highs Despite Insider Selling
• MongoDB Is Surging—And the Next Catalyst Is Almost Here

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.